Exactech, Inc. (NASDAQ:EXAC) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of $0.24 per share for the quarter. Exactech has set its Q3 guidance at $0.23-0.25 EPS and its FY17 guidance at $1.27-1.31 EPS.

Exactech (NASDAQ:EXAC) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $67.30 million during the quarter, compared to analyst estimates of $67.75 million. Exactech had a net margin of 0.30% and a return on equity of 7.39%. Exactech’s revenue was up 1.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.31 EPS. On average, analysts expect Exactech to post $1.29 EPS for the current fiscal year and $1.47 EPS for the next fiscal year.

Exactech, Inc. (NASDAQ:EXAC) opened at 32.00 on Monday. The company has a market cap of $459.14 million, a price-to-earnings ratio of 615.38 and a beta of 1.01. The company’s 50 day moving average is $31.87 and its 200 day moving average is $30.09. Exactech, Inc. has a 1-year low of $22.20 and a 1-year high of $34.25.

In related news, Director Fern Watts sold 1,013 shares of Exactech stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total value of $29,417.52. Following the completion of the transaction, the director now owns 4,727 shares in the company, valued at $137,272.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.30% of the stock is owned by insiders.

EXAC has been the subject of a number of recent research reports. BidaskClub downgraded shares of Exactech from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Gabelli reiterated a “buy” rating on shares of Exactech in a research note on Monday, July 31st. Finally, Robert W. Baird set a $34.00 price target on shares of Exactech and gave the stock a “buy” rating in a research note on Sunday, October 15th.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/exactech-inc-exac-set-to-announce-quarterly-earnings-on-monday.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Earnings History for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.